Equities

Paragon 28 Inc

Paragon 28 Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)10.22
  • Today's Change-0.21 / -2.01%
  • Shares traded514.64k
  • 1 Year change+0.69%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 19:39 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy2
Outperform4
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 5 analysts offering 12 month price targets for Paragon 28 Inc have a median target of 13.00, with a high estimate of 20.00 and a low estimate of 12.00. The median estimate represents a 24.64% increase from the last price of 10.43.
High91.8%20.00
Med24.6%13.00
Low15.1%12.00

Earnings history & estimates in USD

On Nov 12, 2024, Paragon 28 Inc reported 3rd quarter 2024 losses of -0.150 per share. This result was in line with the consensus of the 5 analysts following the company and under-performed last year's 3rd quarter results by 50.00%.
The next earnings announcement is expected on Mar 03, 2025.
Average growth rate-22.74%
Paragon 28 Inc reported annual 2023 losses of -0.58 per share on Feb 29, 2024.
Average growth rate-102.19%
More ▼

Revenue history & estimates in USD

Paragon 28 Inc had 3rd quarter 2024 revenues of 62.34m. This bettered the 60.58m consensus of the 6 analysts covering the company. This was 19.79% above the prior year's 3rd quarter results.
Average growth rate+4.41%
Paragon 28 Inc had revenues for the full year 2023 of 216.39m. This was 19.30% above the prior year's results.
Average growth rate+21.15%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.